Sugi Predict

Sugi Predict / Compounds / SCHEMBL1536413

SCHEMBL1536413

SCHEMBL1536413

O=c1[nH]ccc2ccc(F)cc12

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PARP1 P09874 2/20 0.53
▸ AHR P35869 2/20 0.53
▸ CHEK1 O14757 4/20 0.47
▸ TYMS P04818 2/20 0.45
▸ JAK2 O60674 8/20 0.44
▸ JAK3 P52333 2/20 0.44
▸ IKBKB O14920 1/20 0.42
▸ MAPK13 O15264 1/20 0.42
▸ DAPK3 O43293 1/20 0.42
▸ PRKD3 O94806 1/20 0.42
▸ FYN P06241 1/20 0.42
▸ RET P07949 1/20 0.42
▸ HCK P08631 1/20 0.42
▸ PDGFRB P09619 1/20 0.42
▸ PIM1 P11309 1/20 0.42
▸ FGFR1 P11362 1/20 0.42
▸ PDGFRA P16234 1/20 0.42
▸ PRKCA P17252 1/20 0.42
▸ PRKACA P17612 1/20 0.42
▸ FLT1 P17948 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30673402 1.00 PARP1 (0.53) PARP1AHRCHEK1TYMSJAK2
Trifluoromethanesulfonic Acid SCHEMBL27781740 0.86 PARP1 (0.42) PARP1AHRCHEK1TYMSJAK2
SCHEMBL1551818 0.84 AHR (0.53) PARP1AHRCHEK1TYMSJAK2
SCHEMBL29809657 0.84 AHR (0.53) PARP1AHRCHEK1TYMSJAK2
SCHEMBL28392020 0.83 PARP1 (0.43) PARP1AHRCHEK1TYMSJAK2
SCHEMBL3314460 0.78 GPR84 (0.52) PARP1CHEK1PRKACAMAP2K1ROCK1
SCHEMBL1536457 0.76 CHEK1 (0.77) PARP1AHRCHEK1TYMS
SCHEMBL1868599 0.76 AHR (0.53) PARP1AHRCHEK1TYMSJAK2
SCHEMBL3004117 0.76 PARP1 (0.53) PARP1CHEK1TYMSJAK2PRKACA
SCHEMBL31352392 0.76 CHEK1 (0.77) PARP1AHRCHEK1TYMS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 177 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025024663-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2025-01-30 — — WO claimed
US-12459922-B2 PARP7 inhibitors GILEAD SCIENCES, INC. (US) 2025-11-04 — — US disclosed
EP-4134364-B1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RES INC (US) 2025-07-30 — — EP disclosed
WO-2025133395-A1 BICYCLIC (HETERO)ARYLENE WRN INHIBITORY COMPOUNDS FORX THERAPEUTICS AG (CH) 2025-06-26 — — WO disclosed
WO-2025024663-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2025-01-30 — — WO disclosed
US-20240182490-A1 BROMODOMAIN INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2024-06-06 — — US disclosed
EP-3893645-B1 SUBSTITUTED ARYLMETHYLUREAS AND HETEROARYLMETHYLUREAS, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORP (CA) 2024-04-17 — — EP disclosed
US-11884680-B2 Bromodomain inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-01-30 — — US disclosed
US-11753393-B2 Dihydroorotate dehydrogenase inhibitors JANSSEN BIOTECH, INC. 2023-09-12 — — US disclosed
EP-4134364-A2 BROMODOMAIN INHIBITORS Celgene Quanticel Research, Inc. (US) 2023-02-15 — — EP disclosed
US-20050090432-A1 Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus BRISTOL-MYERS SQUIBB COMPANY 2005-04-28 — — US disclosed
EP-1505963-A1 HEPATITIS C VIRUS INHIBITORS Bristol-Myers Squibb Company (US) 2005-02-16 — — EP disclosed
WO-2004094452-A2 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-04 — — WO disclosed
WO-2004094452-A2 MACROCYCLIC ISOQUINOLINE PEPTIDE INHIBITORS OF HEPATITIS C VIRUS BRISTOL-MYERS SQUIBB COMPANY (US) 2004-11-04 — — WO disclosed
US-20040122223-A1 Non-natural nucleotides and dinucleotides CELLTECH R & D LIMITED (GB) 2004-06-24 — — US disclosed
US-20040106559-A1 Hepatitis C virus inhibitors BRISTOL-MYERS SQUIBB COMPANY 2004-06-03 — — US disclosed
EP-1368366-A1 NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES Celltech R & D Limited (GB) 2003-12-10 — — EP disclosed
WO-2003099274-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 — — WO disclosed
WO-2003099274-A1 HEPATITIS C VIRUS INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 — — WO disclosed
WO-2002062816-A1 NON-NATURAL NUCLEOTIDES AND DINUCLEOTIDES CELLTECH R & D LIMITED (GB) 2002-08-15 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11753393-B2 Dihydroorotate dehydrogenase inhibitors DHODH, DLD, DPYD PARP1 1582/4885AHR 1611/4885CHEK1 2379/4885
US-20240182490-A1 BROMODOMAIN INHIBITORS BRD3, EP300, BRPF3 PARP1 135/4885AHR 2259/4885CHEK1 429/4885
US-20050090432-A1 Macrocyclic isoquinoline peptide inhibitors of Hepatitis C virus VIP, QPCT, HCCS PARP1 3852/4885AHR 3101/4885CHEK1 3054/4885
US-20040122223-A1 Non-natural nucleotides and dinucleotides P2RY1, P2RY11, P2RY13 PARP1 543/4885AHR 2345/4885CHEK1 2444/4885
US-12459922-B2 PARP7 inhibitors PARP1, PARP11, PARP2 PARP1 1/4885AHR 2502/4885CHEK1 59/4885
US-20040106559-A1 Hepatitis C virus inhibitors HAVCR2, HCCS, RNASE1 PARP1 2682/4885AHR 1821/4885CHEK1 2812/4885
US-11884680-B2 Bromodomain inhibitors BRD3, EP300, BRPF3 PARP1 135/4885AHR 2259/4885CHEK1 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.